Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress
Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, has shown substantial efficacy in cancer treatment. However, its associated side effects, particularly chemotherapy-induced peripheral neuropathic pain (CIPNP), continue to challenge cancer survivors globally. Clinically, it freq...
Saved in:
| Main Authors: | Yuxin Jiang, Jie Shi, Wenping Wang, Haozhe Piao, Huini Yao, Jun Yu, Zhenzhu Zhai, Qian Liu, Ningxin Li, Jiaqing Fu, Yue Shen, Shengbo Jin, Mingzhu Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1609791/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation and application analysis of animal models of PIPNP based on data mining
by: Yu Jun, et al.
Published: (2025-07-01) -
Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer
by: Fei-Yu Wang, et al.
Published: (2025-03-01) -
Infrared thermography in clinical practice: a literature review
by: Qian Liu, et al.
Published: (2025-01-01) -
Oxaliplatin combined with capecitabine therapy and comprehensive nursing in advanced colorectal cancer patients
by: Dan Kuang, et al.
Published: (2025-07-01) -
Can Cobalamin prevent Oxaliplatin induced peripheral neuropathy?
by: Naza Shakir Shareef Shekhany, et al.
Published: (2023-06-01)